

1 April 2019

Ms Anjuli Sinniah
Senior Adviser
Listings Compliance (Perth)
ASX Limited
Perth WA 6000
E: ListingsCompliancePerth@asx.com.au

Dear Anjuli

Further to your telephone call and in response to your letter dated 1 April 2019, we respond to each of your questions as follows:

1. BARD1 Life Sciences Limited (“the Company” or “BD1”) is not aware of any information concerning it that has not been announced to the market.
2. N/A
3. The Company previously announced on 18/5/18 that it had signed an agreement with Thermo Fisher Scientific to develop a research-use-only (RUO) multiplex autoantibody test system using ProcartaPlex® Technology for use in BARD1’s research and evaluation and ‘*The custom research assay development project will commence in May-18 and is expected to take approximately **nine months***’. Further announcements including the AGM presentation released on 30/11/18 included an expected timeline for completion of the assay development program of 1Q19. The Company subsequently revised this expectation in our Appendix 4C released on 25/1/19 and its Appendix 4D released on 28/2/19 to expected completion in **1H19**, as per the excerpt below:

Assay Development Program

The Assay Development program with our contract development partner Thermo Fisher Scientific to transfer and develop the research BARD1 assay using ProcartaPlex® Technology for performance on Luminex® instrumentation progressed during the quarter. The feasibility phase was successfully completed in December 2018 and the program has now entered the development phase.

The initial work is to transfer and optimise the BARD1-Ovarian cancer test on the Luminex platform with expected completion in 1H19. If successful, further work is then expected to be undertaken to optimise the BARD1-Breast cancer test on the same platform in readiness to commence clinical studies for both BARD1-Breast and BARD1-Ovarian to evaluate clinical performance in 2H19, followed by expected launch as Laboratory Developed Tests (LDTs) in 2021.

The Company is not aware of any other explanation for the recent trading in its securities.

4. The Company is in compliance with the Listing Rules and, in particular Listing Rule 3.1 which relates to continuous disclosure.
5. The Company confirms that the above responses have been authorised and approved under its published continuous disclosure policy.

Yours faithfully



Pauline Collinson
Company Secretary



1 April 2019

Ms Pauline Collinson
Company Secretary
Bard1 Life Sciences Limited

By email:

Dear Ms Collinson

Bard1 Life Sciences Limited ('BD1'): Price Query

We note the change in the price of BD1's securities from a close of \$0.016 on 29 March 2019 to an intraday high of \$0.02 today.

We also note the significant increase in the volume of BD1's securities traded today.

Request for Information

In light of this, ASX asks BD1 to respond separately to each of the following questions and requests for information:

1. Is BD1 aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is BD1 relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in BD1's securities would suggest to ASX that such information may have ceased to be confidential and therefore BD1 may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that BD1 may have for the recent trading in its securities?
4. Please confirm that BD1 is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that BD1's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of BD1 with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **10.30 AM AWST today Monday, 1 April 2019**. If we do not have your response by then, ASX will likely suspend trading in BD1's securities under Listing Rule 17.3. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, BD1's obligation is to disclose the information

“immediately”. This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market. Your response should be sent to me by e-mail at ListingsCompliancePerth@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rules 3.1 and 3.1A

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities. Exceptions to this requirement are set out in Listing Rule 3.1A. In responding to this letter, you should have regard to BD1’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance *Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that BD1’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in BD1’s securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above ASX will likely suspend trading in BD1’s securities under Listing Rule 17.3.

Enquiries

If you have any queries or concerns about any of the above, please contact me immediately.

Regards

Anjuli Sinniah
Senior Adviser, Listings Compliance (Perth)